
Antibiotics, Journal Year: 2024, Volume and Issue: 13(9), P. 805 - 805
Published: Aug. 25, 2024
With approximately half a billion events per year, lower respiratory tract infections (LRTIs) represent major challenge for the global public health. Among LRTI cases, those caused by Gram-negative bacteria (GNB) are associated with poorer prognostic. Standard-of-care etiologic diagnostics is lengthy and difficult to establish, more than of cases remaining microbiologically undocumented. Recently, syndromic molecular diagnostic panels became available, enabling simultaneous detection tens pathogen-related antimicrobial-resistance genetic markers within few hours. In this narrative review, we summarize available data on performance in GNB pneumonia, highlighting main strengths limitations these assays, as well factors influencing their clinical utility. We searched MEDLINE Web Science databases relevant English-language articles. Molecular assays have higher analytical sensitivity cultural methods, show good agreement standard-of-care regarding pathogens, including GNB, identification frequent patterns resistance antibiotics. Clinical trials reported encouraging results usefulness antibiotic stewardship. By providing early information presence pathogens probable phenotypes, assist choice targeted therapy, shortening time from sample collection appropriate antimicrobial treatment, reducing unnecessary use.
Language: Английский